The anti-atherosclerosis effects of the synthetic LXR agonists GW3965 and T0901317 have been further demonstrated in other atherosclerosis models, such as apoE-deficient (apoE−/−) and LDLR−/− mice (Joseph et al., 2002; Terasaka et al., 2003). Here, LDLR is linked to atherosclerosis.